Cambrex Reports Fourth Quarter and Full-Year 20...( EAST RUTHERFORD N.J. Feb. 14 /- C...),Health

EAST RUTHERFORD, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) reports fourth quarter and full-year 2007 results for the period ended December 31, 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )

Summary

-- Fourth quarter 2007 sales increased 5.7% (-0.2% excluding foreign

currency) compared to fourth quarter 2006. Full year sales were up

6.7% (2.0% excluding foreign currency) compared to 2006.

-- Gross Margin for the quarter increased to 34.9% of sales compared to

33.5% last year. Full year Gross Margin increased to 36.1% compared

to 35.4% in 2006.

-- Operating Profit before corporate, strategic alternatives and

restructuring expenses was $13.3 million or 19.1% of sales in the

fourth quarter of 2007 versus $12.9 million or 19.6% last year. For

the full year, Operating Profit before corporate, strategic

alternatives and restructuring expenses was $51.1 million or 20.2% of

sales, versus $49.2 million or 20.8% for 2006.

-- Debt, net of cash, was $63.3 million at the end of 2007.

-- Sales growth for 2008 is expected to be between 5% and 10% and

Adjusted EBITDA (EBITDA before restructuring and strategic

alternatives costs) is expected to be between $53 and $57 million.

Discontinued Operations and Basis of Reporting

As previously reported, Cambrex sold its Bioproducts and Biopharma businesses (the "Bio Businesses") to Lonza for $463.9 million (after working capital adjustments) in February 2007 and sites in Cork, Ireland and Landen, Bel
'/>"/>